Business Wire

MA-ROCKET-SOFTWARE

Share
Rocket Software Names Milan Shetti as Next CEO

Rocket Software , a global technology leader that develops enterprise software used by the world’s largest public and private sector companies, today named Milan Shetti the company’s next CEO, effective November 5. Milan will also retain his President title. Current CEO and co-founder Andy Youniss will become Executive Chairman, providing strategic insights and guidance to Rocket® in important areas where he has experience and expertise. Andy will also remain on Rocket’s Board of Directors.

“From Rocket’s creation almost 32 years ago, we set out to build a long-lasting software company that would make a difference in the world,” Youniss said. “I am incredibly proud of the company we have built, our 2,500 Rocketeers, the culture we embody, and the core values we live every day. This leadership transition is deeply important to me, and we have been intentional and thoughtful in every step of the process.”

Shetti joined Rocket in 2020 as Business Unit President and was named Rocket President earlier this year, overseeing all products in the company’s portfolio. Most recently, he held senior executive positions at Hewlett Packard Enterprise (HPE), including serving as Senior Vice President and General Manager of the multi-billion dollar storage business unit and previously as Chief Technology Officer of the Datacenter Infrastructure and Storage divisions.

“Milan is the right leader for this moment in Rocket’s history and for its future,” Youniss continued. “I have the utmost confidence that under his leadership, Rocket will continue to put our customers and partners first, deliver innovation and quality that matters, and enable even more legendary outcomes."

“I was captivated by how Rocket’s culture and technology strengthen each other,” said Shetti. “The connection Andy created between Rocket’s core values and the way we serve our customers and partners is what excites me most about leading Rocket in this next era, as we continue to accelerate the modernization of mission-critical systems and solve our customers’ and partners’ most pressing, highly technical challenges.”

“Andy has done a remarkable job building Rocket Software into a global technology leader, thoughtfully guiding the company’s growth and success. We are delighted to be able to continue working with him at the board level,” said David Humphrey, a Managing Director at Bain Capital Private Equity and a member of Rocket’s Board of Directors.

“Milan is an established technology leader with deep background in infrastructure management solutions. We are confident his skills and experience will enable Rocket to continue to advance its mission-critical portfolio of enterprise software solutions while furthering the commitment to its customers, employees and business partners,” added Max de Groen, a Managing Director at Bain Capital Private Equity and a member of Rocket’s Board of Directors.

Shetti began his career at Sun Microsystems as a software developer and advanced through a technical career path to technical director for the company’s data management group. After Sun Microsystems, Shetti led business development for IBRIX, Inc. before assuming the chief executive position. He holds a PhD in computer science from the University of Minnesota and a Master of Science in computer engineering from Syracuse University.

About Rocket Software

Rocket Software empowers organizations to create legendary impact in the world through innovation in legacy technologies. With deep expertise in IBM Z®, IBM Power®, and database and connectivity solutions, Rocket provides solutions that power tens of thousands of global businesses, solving real problems and making real-world impact. Rocket is a privately held U.S. corporation headquartered in the Boston area with centers of excellence strategically located throughout North America, Europe, Asia, and Australia. Rocket is a portfolio company of Bain Capital Private Equity.

Legacy Powers Legendary™

© 2021 Rocket Software, Inc. or its affiliates. All Rights Reserved.

Rocket® is a trademark of Rocket Software, Inc. and its subsidiaries, registered in the United States and other jurisdictions worldwide. All other trademarks cited herein are the property of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press release

1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi

Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release

Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment

Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press release

With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions. Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain d

Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release

PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an

TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release

TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye